| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/02/2001 | CA2398615A1 Benzoxathiepino[3,4-b]pyridine derivatives, process for their preparation and their use as medicaments |
| 08/02/2001 | CA2398611A1 Vaccine for the prophylactic or therapeutic immunization against hiv |
| 08/02/2001 | CA2398561A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | CA2398546A1 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | CA2398435A1 Novel ligands and methods for preparing same |
| 08/02/2001 | CA2398427A1 Cancer cell implantation inhibitors |
| 08/02/2001 | CA2398304A1 A new process for the preparation of latanoprost |
| 08/02/2001 | CA2398288A1 Ibuprofen containing active agent preparation |
| 08/02/2001 | CA2398227A1 17 human secreted proteins |
| 08/02/2001 | CA2398206A1 Pharmaceutical preparation and method for treatment of diabetes |
| 08/02/2001 | CA2398199A1 Novel therapeutic agents that use a .beta.3 agonist |
| 08/02/2001 | CA2398186A1 Therapeutic agent for reperfusion injury comprising integrin .alpha.v.beta.3 antagonists |
| 08/02/2001 | CA2398173A1 Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases |
| 08/02/2001 | CA2398139A1 Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha |
| 08/02/2001 | CA2397831A1 Enhanced propertied pharmaceuticals |
| 08/02/2001 | CA2397758A1 Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate |
| 08/02/2001 | CA2397755A1 Eye drops containing 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy)-2-propylphenoxy)butyic acid for the use in the treatment of allergic eye disease |
| 08/02/2001 | CA2397754A1 Nitrate salts of antimicrobial agents |
| 08/02/2001 | CA2397523A1 Combination therapy for cancer |
| 08/02/2001 | CA2397493A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | CA2396781A1 A method of administering a medicinal aerosol formulation |
| 08/02/2001 | CA2396628A1 Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia |
| 08/02/2001 | CA2396596A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| 08/02/2001 | CA2396593A1 Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
| 08/02/2001 | CA2396372A1 Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| 08/02/2001 | CA2395730A1 Selective estrogen receptor modulators in combination with estrogens |
| 08/02/2001 | CA2395447A1 Palatable arginine compounds and uses thereof for cardiovascular health |
| 08/02/2001 | CA2395446A1 Compositions, kits, and methods for cardiovascular health |
| 08/02/2001 | CA2395298A1 Propionic acid derivatives and their use in the treatment of diabetes and obesity |
| 08/02/2001 | CA2394525A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| 08/02/2001 | CA2394292A1 Isatine derivatives with neurotrophic activity |
| 08/02/2001 | CA2366759A1 In vivo stain compounds and methods of use to identify dysplastic tissue |
| 08/02/2001 | CA2297706A1 Anticonvulsive and antiallergic/anti-asthmatic pyrazolo-(3,4-d)pyrimidines having affinity for the adenosine receptor, and process for their preparation |
| 08/01/2001 | EP1120723A2 Identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists and associated pharmacophore models and screening methods |
| 08/01/2001 | EP1120477A2 Method of manufacturing a tin layer on the internal surface of copper alloy hollow elements |
| 08/01/2001 | EP1120466A2 Use of negative regulation elements for nerve-specific expression of transgenes |
| 08/01/2001 | EP1120464A2 Stabilizing peptides, polypeptides and antibodies which include them |
| 08/01/2001 | EP1120419A1 Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance |
| 08/01/2001 | EP1120417A2 Xanthine derivatives for the treatment of cerebrovascular disorders |
| 08/01/2001 | EP1120416A1 Pyrido[2.3-b][1,4]benzodiazepinones as M2 receptor ligand for the treatment of neurological disorders |
| 08/01/2001 | EP1120410A1 Nicotinic acid esters useful as CNS agents and having affinity for 5-HT receptors |
| 08/01/2001 | EP1120409A1 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation |
| 08/01/2001 | EP1120408A1 Remedies for motor dysfunction and gapdh expression inhibitors |
| 08/01/2001 | EP1120407A1 Cysteine derivatives |
| 08/01/2001 | EP1120120A1 Tablets immediately disintegrating in the oral cavity |
| 08/01/2001 | EP1120117A1 Method of increasing the production of eggs and strengthening eggshells in poultry |
| 08/01/2001 | EP1120116A1 Antimycotic drug composition |
| 08/01/2001 | EP1120115A2 Skin-friendly plasters for the transdermal administration of non-steroidal antirheumatic agents |
| 08/01/2001 | EP1120114A2 Compositions and methods for treating conditions responsive to estrogen |
| 08/01/2001 | EP1120113A2 Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormone |
| 08/01/2001 | EP1120107A1 Nutritional supplement based on blackcurrant seed oil |
| 08/01/2001 | EP1120100A1 Antibacterial agents and process for producing the same |
| 08/01/2001 | EP1119643A1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-$g(a) (TNF-$g(a)) EXPRESSION |
| 08/01/2001 | EP1119630A1 Nucleic acid constructs for genetic immunisation |
| 08/01/2001 | EP1119629A2 Oxidoreductase molecules |
| 08/01/2001 | EP1119619A2 Nlk1 -interacting proteins |
| 08/01/2001 | EP1119580A1 ANTISENSE MODULATION OF EXPRESSION OF TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTORS (TRAFs) |
| 08/01/2001 | EP1119579A1 Antisense modulation of bcl-x expression |
| 08/01/2001 | EP1119573A2 Bipyridine manganese complexes |
| 08/01/2001 | EP1119571A2 Tricyclic delta3-piperidines as alpha2-antagonists |
| 08/01/2001 | EP1119570A1 Tricyclic delta3-piperidines as pharmaceuticals |
| 08/01/2001 | EP1119568A1 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| 08/01/2001 | EP1119567A1 Quinazoline derivatives |
| 08/01/2001 | EP1119566A1 Novel heterocyclyl-methyl-substituted pyrazoles |
| 08/01/2001 | EP1119565A1 Cytotoxic alkaloids (halitulin) |
| 08/01/2001 | EP1119564A1 Aryl- 4-fluoro-4- (2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl -methanone derivatives as 5-ht1 receptor antagonists |
| 08/01/2001 | EP1119563A1 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 08/01/2001 | EP1119562A1 2,3-dihydro-1h-isoindole derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 08/01/2001 | EP1119559A1 3-phenyl-pyrones |
| 08/01/2001 | EP1119557A1 Indeno-, naphto- and benzocyclohepta dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments |
| 08/01/2001 | EP1119555A1 Biphenylene lactams as prostaglandin receptor ligands |
| 08/01/2001 | EP1119553A1 Monomeric and dimeric heterocycles, and therapeutic uses thereof |
| 08/01/2001 | EP1119552A1 Ureidopiperidine derivatives as selective human nk 3? receptor antagonists |
| 08/01/2001 | EP1119551A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 08/01/2001 | EP1119550A1 2-substituted heterocyclic sulfonamides |
| 08/01/2001 | EP1119548A1 Pyrrole-2,5-diones as gsk-3 inhibitors |
| 08/01/2001 | EP1119544A1 Energetic nitramine-linked azoles and hydroxylammonium salts as oxidizers, initiators and gas generators |
| 08/01/2001 | EP1119543A1 N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor |
| 08/01/2001 | EP1119542A1 Prostaglandin receptor ligands |
| 08/01/2001 | EP1119539A1 A process for the preparation of 4,4'-dihalogen-o-hydroxydiphenyl compounds |
| 08/01/2001 | EP1119375A1 Methods and adjuvants for stimulating mucosal immunity |
| 08/01/2001 | EP1119373A1 Oxybutynin formulations and methods of use |
| 08/01/2001 | EP1119372A1 Composition and method for treating allergic diseases |
| 08/01/2001 | EP1119366A1 Animal stereotypy |
| 08/01/2001 | EP1119363A2 Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug |
| 08/01/2001 | EP1119362A1 Method of using tetracycline compounds to enhance interleukin-10 production |
| 08/01/2001 | EP1119361A2 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| 08/01/2001 | EP1119360A1 Methods and compositions for increasing intestinal absorption of fats |
| 08/01/2001 | EP1119359A1 2-methyl-thieno-benzodiazepine formulation |
| 08/01/2001 | EP1119358A1 Use of an nk-1 receptor antagonist for treating cognitive disorders |
| 08/01/2001 | EP1119357A1 C3a receptor ligands |
| 08/01/2001 | EP1119356A1 Radiolabeled neurokinin-1 receptor antagonists |
| 08/01/2001 | EP1119355A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 08/01/2001 | EP1119354A1 Peripherally acting anti-pruritic opiates |
| 08/01/2001 | EP1119353A1 Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
| 08/01/2001 | EP1119352A1 A method for the treatment of ocular oxidative stress |
| 08/01/2001 | EP1119351A2 Use of catechol derivatives as proteinase inhibitors |
| 08/01/2001 | EP1119350A2 Rar antagonists as male anti-fertility agents |
| 08/01/2001 | EP1119349A2 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
| 08/01/2001 | EP1119338A2 Compositions which contain triterpenes for regulating hair growth |